Anupam Rasayan India Limited , a prominent player in the specialty chemicals sector, has submitted its monitoring agency report for the quarter ended September 30, 2025, detailing the utilization of proceeds from its Rs 550 crore preferential issue. The report, prepared by CRISIL Ratings Limited, reveals that the company has fully utilized the funds in line with its stated objectives.

Breakdown of Fund Utilization

The preferential issue proceeds were allocated and utilized as follows:

Loan Repayment

Anupam Rasayan has fully utilized the allocated Rs 429.69 crore for the repayment of term loans. This strategic move is expected to strengthen the company's balance sheet by reducing its debt burden and potentially improving its financial ratios.

General Corporate Purposes

Out of the Rs 120.31 crore earmarked for general corporate purposes, the company has utilized Rs 119.71 crore. The majority of this amount, Rs 101.90 crore, was used for vendor payments, demonstrating the company's commitment to maintaining strong relationships with its suppliers and ensuring smooth operations.

Compliance and Transparency

The monitoring agency report confirms that there have been no deviations from the stated objectives of the preferential issue. This adherence to the declared use of funds underscores Anupam Rasayan's commitment to transparency and good corporate governance practices.

Unutilized Funds

A small portion of the funds, amounting to Rs 0.60 crore, remains unutilized as of the end of the quarter. This amount is currently held in the company's preferential issue account.

Timely Implementation

The report indicates that there were no delays in the implementation of the stated objectives. This timely utilization of funds suggests efficient financial management and execution capabilities on the part of Anupam Rasayan's leadership.

The full utilization of the preferential issue proceeds, primarily for debt repayment and operational expenses, may potentially contribute to improved financial health and operational efficiency for Anupam Rasayan India Limited. Investors and stakeholders can take confidence in the company's adherence to its stated objectives and the transparent reporting of fund utilization.

Anupam Rasayan India Limited , a leading specialty chemicals company, has reported exceptional financial results for the second quarter, showcasing robust growth across key metrics.

Strong Revenue Growth

The company delivered a stellar performance with consolidated revenue from operations of ₹731.40 crore in Q2, marking a remarkable 148.80% year-on-year growth and a 50.50% sequential increase. For the first half, consolidated revenue reached ₹1,217.20 crore, representing an impressive 122.10% year-on-year growth.

Segment-wise Performance

Life Science Related Specialty Chemicals continued to be the primary revenue driver, contributing 84% of total revenue in H1. Within this segment:

• The Pharma segment accounted for 23% and registered a strong 201% YoY growth during H1, driven by new product launches and scale-up of recently commercialized molecules.
• Performance Materials contributed 16% of total revenue in H1, with revenue growing by 306% YoY, supported by the ramp-up of newly launched polymer molecules.

Profitability and Margins

The company reported consolidated EBITDA margins of approximately 19.50% in Q2 and 25.50% for H1. These margins were slightly subdued due to some dispatches made from older inventory. Management expects margins to normalize from Q3 onwards as new contracts and pricing structures take effect.

Order Book and Future Outlook

Anupam Rasayan's order book remains healthy at around ₹14,646.00 crore, spread over 5-7 years. The company expects these orders to contribute approximately ₹450.00 crore in revenue. Management has guided for over 50% revenue growth, largely attributed to recovery in agrochemicals sales and growth in polymer and pharma segments.

Geographical Performance

The US market has shown phenomenal growth and continues to be a key growth driver for the company. Importantly, the majority of Anupam Rasayan's products fall under the exempt category for recently imposed US tariffs, ensuring that exports remain unaffected by cost pressures.

Working Capital Management

The company has made significant progress in optimizing its balance sheet and improving working capital efficiency:

Management expects to further reduce working capital days to approximately 200 in the near term.

Debt Reduction

With the receipt of ₹277.50 crore from warrants in July, the company used ₹175.00 crore towards repayment of term debt, resulting in a net debt of ₹730.00 crore at the consolidated level.

Anand Desai, Managing Director of Anupam Rasayan, commented on the results: "This quarter truly reflects the best of Anupam Rasayan—our agility, customer trust, and execution strength—supported by a favorable industry environment and renewed momentum across global markets."

The company's strong performance in Q2 positions it well for sustained growth and profitability in the coming periods, reflecting the resilience of its business model, strong customer relationships, and operational excellence.